TY - JOUR
T1 - Cognition in non-demented Parkinson's disease vs essential tremor
T2 - A population-based study
AU - Sánchez-Ferro,
AU - Benito-León, J.
AU - Louis, E. D.
AU - Contador, I.
AU - Hernández-Gallego, J.
AU - Puertas-Martín, V.
AU - Bermejo-Pareja, F.
N1 - Funding Information:
The Spanish Health Research Agency and the Spanish Office of Science and Technology supported NEDICES. Dr. Alvaro Sanchez-Ferro has received funding from Consejería de Educación, Juventud y Deporte of Comunidad de Madrid, and the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) under REA grant agreement n° 291820. Dr. Sánchez-Ferro has also been supported by the Madrid-MIT M+Vision Consortium (Comunidad de Madrid). Dr. Benito-León is supported by the National Institutes of Health, Bethesda, MD, USA (NINDS #R01 NS39422), the Commission of the European Union (grant ICT-2011-287739, NeuroTREMOR), and the Spanish Health Research Agency (grant FIS PI12/01602). Dr. Louis has received research support from the National Institutes of Health: NINDS #R01 NS042859 (principal investigator), NINDS #R01 NS39422 (principal investigator), NINDS #R01 NS086736 (principal investigator), NINDS #R01 NS073872 (principal investigator), NINDS #R01 NS085136 (principal investigator), and NINDS #R01 NS088257 (principal investigator). Dr. Bermejo-Pareja is supported by NINDS #R01 NS39422 from the National Institutes of Health, Bethesda, MD, USA, and from the Commission of the European Union (grant ICT-2011-287739, NeuroTREMOR)
Funding Information:
Funding information The Spanish Health Research Agency and the Spanish Office of Science and Technology supported NEDICES. Dr. Alvaro Sanchez-Ferro has received funding from Consejería de Educación, Juventud y Deporte of Comunidad de Madrid, and the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement n° 291820. Dr. Sánchez-Ferro has also been supported by the Madrid-MIT M+Vision Consortium (Comunidad de Madrid). Dr. Benito-León is supported by the National Institutes of Health, Bethesda, MD, USA (NINDS #R01 NS39422), the Commission of the European Union (grant ICT-2011-287739, NeuroTREMOR), and the Spanish Health Research Agency (grant FIS PI12/01602). Dr. Louis has received research support from the National Institutes of Health: NINDS #R01 NS042859 (principal investigator), NINDS #R01 NS39422 (principal investigator), NINDS #R01 NS086736 (principal investigator), NINDS #R01 NS073872 (principal investigator), NINDS #R01 NS085136 (principal investigator), and NINDS #R01 NS088257 (principal investigator). Dr. Bermejo-Pareja is supported by NINDS #R01 NS39422 from the National Institutes of Health, Bethesda, MD, USA, and from the Commission of the European Union (grant ICT-2011-287739, NeuroTREMOR) The authors would like to thank Dr. Carmen Gasca for her suggestions to improve this publication. The authors gratefully acknowledge the vital help of the other members of the NEDICES Study Group: Additional information about collaborators of the NEDICES study can be found on the Web (http://www.ciberned.es/estudio-nedices).
Publisher Copyright:
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2017/11
Y1 - 2017/11
N2 - Objectives: Patients with Parkinson's disease (PD) and essential tremor (ET) have a higher risk of cognitive impairment than age-matched controls. Only a few small studies (11-18 subjects per group) have directly compared the cognitive profile of these conditions. Our aim was to compare the cognitive profile of patients with these two conditions to each other and to healthy individuals in a population-based study of non-demented participants. Materials and methods: This investigation was part of the NEDICES study, a survey of the elderly in which 2438 dementia-free participants underwent a short neuropsychological battery. We used nonparametric techniques to evaluate whether there are differences and/or a gradient of impairment across the groups (PD, ET, and controls). Also, we performed a head-to-head comparison of ET and PD, adjusting for age and education. Results: Patients with PD (N=46) and ET (N=180) had poorer cognition than controls (N=2212). An impaired gradient of performance was evident. PD scored lower than ET, and then each of these lower than controls, in memory (P<.05) and verbal fluency (P<.001) tasks. When we compared PD and ET, the former had lower scores in verbal fluency (P<.05), whereas the later had a poorer cognitive processing speed (P<.05). Conclusions: This large population-based study demonstrates that both conditions influence cognitive performance, that a continuum exists from normal controls to ET to PD (most severe), and that although deficits are in many of the same cognitive domains, the affected cognitive domains do not overlap completely.
AB - Objectives: Patients with Parkinson's disease (PD) and essential tremor (ET) have a higher risk of cognitive impairment than age-matched controls. Only a few small studies (11-18 subjects per group) have directly compared the cognitive profile of these conditions. Our aim was to compare the cognitive profile of patients with these two conditions to each other and to healthy individuals in a population-based study of non-demented participants. Materials and methods: This investigation was part of the NEDICES study, a survey of the elderly in which 2438 dementia-free participants underwent a short neuropsychological battery. We used nonparametric techniques to evaluate whether there are differences and/or a gradient of impairment across the groups (PD, ET, and controls). Also, we performed a head-to-head comparison of ET and PD, adjusting for age and education. Results: Patients with PD (N=46) and ET (N=180) had poorer cognition than controls (N=2212). An impaired gradient of performance was evident. PD scored lower than ET, and then each of these lower than controls, in memory (P<.05) and verbal fluency (P<.001) tasks. When we compared PD and ET, the former had lower scores in verbal fluency (P<.05), whereas the later had a poorer cognitive processing speed (P<.05). Conclusions: This large population-based study demonstrates that both conditions influence cognitive performance, that a continuum exists from normal controls to ET to PD (most severe), and that although deficits are in many of the same cognitive domains, the affected cognitive domains do not overlap completely.
KW - epidemiology
KW - movement disorders
KW - neurobehavioral manifestations
KW - neuropsychological profile
KW - neuropsychology
UR - http://www.scopus.com/inward/record.url?scp=85014563372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014563372&partnerID=8YFLogxK
U2 - 10.1111/ane.12752
DO - 10.1111/ane.12752
M3 - Article
C2 - 28261780
AN - SCOPUS:85014563372
SN - 0001-6314
VL - 136
SP - 393
EP - 400
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
IS - 5
ER -